Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6209732 | 0.91 | ALDH1A1 (0.45) | PKMALDH1A1HPGDMAPK1MAPT | |
| SCHEMBL1386085 | 0.91 | MAPK1 (0.51) | PKMALDH1A1HPGDMAPK1MAPT | |
| SCHEMBL4037876 | 0.87 | ALDH1A1 (0.46) | PKMALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL4034713 | 0.87 | ALDH1A1 (0.44) | PKMALDH1A1HPGDMAPK1MAPT | |
| SCHEMBL4033608 | 0.80 | ALOX15 (0.41) | ALDH1A1HPGDMAPK1MAPTPOLB | |
| SCHEMBL6209492 | 0.80 | ALOX15 (0.41) | ALDH1A1HPGDMAPK1MAPTPOLB | |
| SCHEMBL4035745 | 0.78 | MMP1 (0.40) | ALDH1A1USP2MAPK1GAA | |
| SCHEMBL1383797 | 0.77 | PKM (0.60) | PKMALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL1382194 | 0.77 | PKM (0.61) | PKMALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL4032519 | 0.76 | ALDH1A1 (0.62) | PKMALDH1A1HPGDUSP2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | claimed |
| JP-4825664-B2 | — | — | 2011-11-30 | — | — | JP | claimed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | claimed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | claimed |
| EP-1592389-A2 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2005-11-09 | — | — | EP | claimed |
| WO-2004071390-A2 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-08-26 | — | — | WO | claimed |
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | PKM 1747/4885ALDH1A1 610/4885HPGD 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.